Eye care device company Luneau targets Euronext IPO
This article was originally published in Clinica
French ophthalmic equipment specialist Luneau Technology is aiming to raise funds by floating on the Euronext's Alternext market for small- to medium-sized firms. The Chartres-based firm is offering around 825,000 new shares at a price range of E4.64-5.06 from January 15-28 and expects to begin trading on the Paris branch of the Alternext on February 4. Depending on the demand for its shares, Luneau could exercise an extension option and offer an extra 124,000 shares, as well as a Greenshoe option and offer an additional 82,000 to existing shareholders depending on its performance during its first month on the exchange. The Greenshoe option aims to provide stability to an initial public offering post-pricing. Luneau manufactures various devices and accessories for diagnostic and surgical treatment, including keratometers, tonometers and retinographs. It also makes and sells gynaecology materials.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.